Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30685153 | 0.98 | CHEK1 (0.61) | CHEK1CHEK2FYNLTA4HABL1 | |
| SCHEMBL27605045 | 0.84 | ABL1 (0.55) | CHEK1CHEK2LTA4HABL1BCR | |
| SCHEMBL4559856 | 0.84 | AR (0.52) | CHEK1CHEK2ARHDAC2HDAC1 | |
| SCHEMBL420705 | 0.82 | KDM4E (0.55) | LTA4HABL1BCRHPGDSHDAC2 | |
| SCHEMBL1020361 | 0.81 | ABL1 (0.53) | CHEK1CHEK2LTA4HABL1BCR | |
| SCHEMBL27612096 | 0.81 | NQO2 (0.58) | CHEK1CHEK2LTA4HABL1BCR | |
| SCHEMBL1133065 | 0.81 | MAPT (0.53) | LTA4HABL1BCRHDAC2HDAC1 | |
| Carbamic Acid SCHEMBL26695414 | 0.80 | HPGDS (0.54) | LTA4HHPGDSHDAC2HDAC1HDAC3 | |
| SCHEMBL3283049 | 0.79 | HPGDS (0.56) | LTA4HABL1BCRHPGDSHDAC2 | |
| SCHEMBL27889063 | 0.79 | CES2 (0.56) | LTA4HABL1BCRHPGDSHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| CN-118496135-B | Thiourea compound or pharmaceutically acceptable salt thereof and application thereof as immunosuppressant | 中国海洋大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118496135-A | Thiourea compound or pharmaceutically acceptable salt thereof and application thereof as immunosuppressant | 中国海洋大学 | 2024-08-16 | — | — | CN | disclosed |
| US-20240075025-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-03-07 | — | — | US | disclosed |
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| US-20230110554-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | CONSTANT THERAPEUTICS LLC | 2023-04-13 | — | — | US | disclosed |
| EP-3373951-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA | TARIX PHARMACEUTICALS LTD (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10960045-B2 | Methods and compositions for the treatment of epidermolysis bullosa | CONSTANT THERAPEUTICS LLC (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190000809-A1 | ANGIOTENSIN IN TREATING BRAIN CONDITIONS | TARIX PHARMACEUTICALS LTD. | 2019-01-03 | — | — | US | disclosed |
| US-6538144-B2 | Reacting thiophene-3-boronic acids with p-bromobenzaldehydes to form first intermediate, recting it with primary amines to form a second intermediate which is reacted with acyl chlrides, deprotecting to form sulfonamide, then sulfonylurea | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-25 | — | — | US | disclosed |
| US-6538144-B2 | Reacting thiophene-3-boronic acids with p-bromobenzaldehydes to form first intermediate, recting it with primary amines to form a second intermediate which is reacted with acyl chlrides, deprotecting to form sulfonamide, then sulfonylurea | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-25 | — | — | US | disclosed |
| US-6538144-B2 | Reacting thiophene-3-boronic acids with p-bromobenzaldehydes to form first intermediate, recting it with primary amines to form a second intermediate which is reacted with acyl chlrides, deprotecting to form sulfonamide, then sulfonylurea | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-25 | — | — | US | disclosed |
| US-20020188139-A1 | P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-12 | — | — | US | disclosed |
| US-20020188139-A1 | P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-12 | — | — | US | disclosed |
| US-20020188139-A1 | P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-12 | — | — | US | disclosed |
| WO-2002072569-A1 | P-THIENYLBENZYL-AMIDES SERVING AS AGONISTS OF ANGIOTENSIN-(1-7)-RECEPTORS, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072569-A1 | P-THIENYLBENZYL-AMIDES SERVING AS AGONISTS OF ANGIOTENSIN-(1-7)-RECEPTORS, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| CN-1310621-A | Substituted anilide compounds and methods | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188139-A1 | P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use | AGTR1, AGTR2, EDNRA | CHEK1 2555/4885CHEK2 3661/4885FYN 2205/4885 |
| US-20190000809-A1 | ANGIOTENSIN IN TREATING BRAIN CONDITIONS | ACE, AGT, ACE2 | CHEK1 4719/4885CHEK2 4632/4885FYN 794/4885 |
| US-10960045-B2 | Methods and compositions for the treatment of epidermolysis bullosa | ELANE, SERPINB1, ACE | CHEK1 965/4885CHEK2 1037/4885FYN 2801/4885 |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | CHEK1 2820/4885CHEK2 1537/4885FYN 1345/4885 |
| US-20240075025-A1 | Therapy for Mitochondrial Fatty Acid Beta-Oxidation and Transport Disorders | HADHB, HADHA, NDUFAB1 | CHEK1 4733/4885CHEK2 4804/4885FYN 3386/4885 |
| US-20230110554-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | ACE, ACE2, AGTR1 | CHEK1 2351/4885CHEK2 3204/4885FYN 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.